In view of the company’s highly independent board, our strong corporate governance practices and the role of our independent Presiding Director, Monsanto’s board believes that the shareowner proposal is unnecessary and would not strengthen the board’s independence or oversight functions. We believe shareowners interests are best served by maintaining the board’s flexibility to decide the appropriate leadership of the board under the prevailing circumstances.
By: John C. Harrington of Harrington Investments, Inc.
Resolved:Shareholders amend the by-laws, in compliance with applicable law, the Certificate of Incorporation, and with these Bylaws, inserting a new section, as follows:
Section 59h.Notwithstanding other provisions of these Bylaws, the Company shall not indemnify any director for any liability resulting from alleged harm to the natural environment, public health or human rights incurred in his or her capacity as a director, except to the extent such indemnification is required by Delaware Law. The provision, consistent with Section 59g, shall not adversely affect any right or protection of a director existing with respect to any act or omission occurring prior to or at the time of enactment of this provision, and any change in indemnity limits pursuant to this provision shall only be applied to an individual director upon subsequent establishment or renewal of his or her directorship. In the event of a conflict between this provision and other corporate governance documents, applicability shall be determined pursuant to Delaware Law.
Supporting Statement
It is the intent of proponents to ensure that, to the fullest extent allowed by Delaware law, a director will not be indemnified by the Company if such director breaches fiduciary duties to the corporation in relation to alleged harms to the natural environment, public health or human rights.
____________________
OUR BOARD OF DIRECTORS RECOMMENDS A VOTE “AGAINST” THE FOREGOING
PROPOSAL FOR THE FOLLOWING REASONS:
The level of indemnification provided in our Bylaws is authorized under Delaware law.Our Bylaws provide mandatory indemnification of our directors to the fullest extent permitted by Delaware law. Under Delaware law and our Bylaws, in order to be entitled to indemnification, a director must have acted in good faith and in a manner reasonably believed to be in, or not opposed to, the best interests of the company and, with respect to any criminal action or proceeding, had no reasonable cause to believe the conduct was unlawful. The Board believes that this policy properly balances the responsibilities of directors with the need to protect them from the risks of liability.
The proposed Bylaw would make it difficult for directors to exercise their business judgment with respect to matters relating to the natural environment, public health or human rights.The proposed Bylaw would prevent our company from indemnifying a director for liabilities that allege harm to the natural environment, public health or human rights unless the director is successful in defending against such claim, action, suit or proceeding. Under the proposed Bylaw, potential plaintiffs would simply have to assert a claim against a director and some connection to the natural environment, public health or human rights to involve our directors in potentially lengthy, costly and risky litigation. Increased legal action would likely distract the directors subject to such claims, increase legal costs for our company, and make it more difficult and risky for our company to take actions that might be associated with these matters.
The proposed Bylaw would be difficult to interpret and implement with any reasonable certainty.As previously noted, the proposed Bylaw would prevent our company from indemnifying a director for liabilities relating to the natural environment, public health or human rights, unless the director is successful in defending against such claim, action, suit or proceeding. However, no guidance is provided as to the meaning or application of these terms, and each of these concepts is inherently broad and subject to multiple and differing interpretations. In light of the nature of Monsanto’s business, this imprecision would make it particularly difficult for our company to determine whether indemnification would be permitted in connection with any particular claim, action, suit or proceeding. This imprecision could potentially subject Monsanto to multiple challenges by shareowners seeking to enforce the Bylaw provision to advance their own views, standards or agendas.
To attract and retain qualified candidates, Monsanto must provide Board members with reasonable protections against liability that are consistent with those provided by other public companies. Indemnification provisions similar or identical to those currently in place at Monsanto are commonplace among the large public companies with which Monsanto competes for qualified director candidates, and these provisions do not generally contain exceptions like those called for in the shareowner proposal. The frequency of litigation against corporate directors, the expense involved in defending against these lawsuits (whether or not they have any merit), and the uncertainty of the outcome of any such litigation, all make the possibility of
64
personal liability a serious concern for corporate directors. The Board believes that Monsanto will best be able to attract and retain qualified directors if it provides them with appropriate indemnification against liability for actions taken in their capacity as directors.
ACCORDINGLY, OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE
“AGAINST” THIS PROPOSAL, AND YOUR PROXY WILL BE SO VOTED IF THE PROPOSAL
IS PRESENTED UNLESS YOU SPECIFY OTHERWISE.
____________________
Other Matters
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934, as amended, requires all company executive officers, directors, and persons owning more than 10% of any registered class of our capital stock to file reports of ownership and changes in ownership with the SEC. Based solely on the reports received by us or filed with the SEC and on written representations from reporting persons, we believe that all such persons complied with all applicable filing requirements during our 2007 fiscal year, except that Mr. Harper filed a late Form 4 reporting one transaction.
Shareowner Proposals
Proposals Included in Proxy Statement
Proposals of our shareowners that are intended to be presented by such shareowners at our 2009 annual meeting and that shareowners desire to have included in our proxy materials relating to such meeting must be received by us at our principal executive offices no later than 5:00 p.m., Central Time, August 7, 2008, which is 120 calendar days prior to the anniversary of this year’s mailing date. The proposal, including any accompanying supporting statement, may not exceed 500 words. Upon timely receipt of any such proposal, we will determine whether or not to include such proposal in the proxy statement and proxy in accordance with applicable regulations governing the solicitation of proxies.
Proposals Not Included in the Proxy Statement
If a shareowner wishes to present a proposal at our annual meeting in the year 2009 or to nominate one or more directors and the proposal is not intended to be included in our proxy statement relating to that meeting, the shareowner must give advance written notice to us prior to the deadline for such meeting determined in accordance with our bylaws. In general, our bylaws provide that such notice should be addressed to the Secretary and be received at our Creve Coeur Campus no less than 90 days nor more than 120 days prior to the first anniversary of the preceding year’s annual meeting. For purposes of our 2009 annual meeting, such notice must be received not later than October 18, 2008 and not earlier than September 18, 2008. These time limits also apply in determining whether notice is timely for purposes of rules adopted by the SEC relating to the exercise of discretionary voting authority. Our bylaws set out specific requirements that such written notices must satisfy. Any shareowner filing a written notice of nomination for director must describe various matters regarding the nominee and the shareowner, including such information as name, address, occupation and shares held. Any shareowner filing a notice to bring other business before a shareowner meeting must include in such notice, among other things, the text of the proposal or business and the reasons therefore, and other specified matters.
Our bylaws also set out specific eligibility requirements that nominees for director must satisfy, which require nominees to:
- complete and return a written questionnaire with respect to the background and qualification of the nominees and the background of any other person or entity on whose behalf the nomination is being made; and
- provide a written representation and agreement that the nominee:
65
- will abide by the advance resignation requirements of our bylaws in connection with director elections;
- is not and will not become a party to (1) any agreement, arrangement or understanding with, and has not given any commitment or assurance to, any person or entity as to how such prospective nominee, if elected as a director, will act or vote on any issue or question (a “Voting Committment”) that has not been disclosed to us or (2) any Voting Committment that could limit or interfere with the nominee’s ability to comply, if elected as a director, with the nominee’s fiduciary duties under applicable law;
- is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than us with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed therein; and
- would be in compliance if elected as a director and will comply with all of our applicable corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines.
Copies of those requirements will be forwarded to any shareowner upon written request.
Electronic Access to Proxy Materials and Annual Report
Shareowners may view this proxy statement and our 2007 Annual Report to Shareowners over the Internet by accessing our website at http://www.monsanto.com and clicking on the “Investor Information” tab and then clicking on the “Presentations and Financial Reports” tab. Information on our website does not constitute part of this proxy statement.
In addition, most shareowners can elect to receive future proxy statements and annual reports over the Internet instead of receiving paper copies in the mail. If you are a shareowner of record, you can choose this option and save us the cost of producing and mailing these documents by following the instructions on the enclosed proxy card or by following the instructions provided if you vote over the Internet or by telephone. If you hold your shares through a bank or broker, please refer to the information provided by that entity for instructions on how to elect to receive future proxy statements and annual reports over the Internet.
Other Information
Our board of directors knows of no matter, other than those referred to in this proxy statement, which will be presented at the meeting. However, if any other matters, including a shareowner proposal excluded from this proxy statement pursuant to the rules of the SEC, properly come before the meeting or any of its adjournments, the person or persons voting the proxies will vote in accordance with their best judgment on such matters. Should any nominee for director be unable to serve or for good cause will not serve at the time of the meeting or any adjournments thereof, the persons named in the proxy will vote for the election of such other person for such directorship as our board of directors may recommend, unless, prior to the meeting, the board has eliminated that directorship by reducing the size of the board. The board is not aware that any nominee herein will be unable to serve or for good cause will not serve as a director.
We will bear the expense of preparing, printing and mailing this proxy material, as well as the cost of any required solicitation. Our directors, officers or employees may solicit proxies on our behalf. We have engaged Morrow & Co., Inc. to assist us in the solicitation of proxies. We expect to pay Morrow approximately $10,000 for these services plus expenses. In addition, we will reimburse banks, brokerage firms and other custodians, nominees and fiduciaries for reasonable expenses incurred in forwarding proxy materials to beneficial owners of our stock and obtaining their proxies.
66
You are urged to vote promptly by marking, signing, dating, and returning your proxy card or by voting by telephone or over the Internet. You may revoke your proxy at any time before it is voted; and if you attend the meeting, as we hope you will, you may vote your shares in person.
| By Order of the Board of Directors, MONSANTO COMPANY |
| |
| |
| |
| DAVID F. SNIVELY Secretary |
| |
| December 5, 2007 |
67
APPENDIX A |
|
INFORMATION REGARDING OUR FORMATION |
Prior to Sept. 1, 1997, a corporation that was then known as Monsanto Company (Former Monsanto) operated an agricultural products business (the Ag Business), pharmaceuticals and nutrition business (the Pharmaceuticals Business) and a chemical products business (the Chemicals Business). Former Monsanto is today known as Pharmacia. Pharmacia is now a wholly owned subsidiary of Pfizer Inc., which together with its subsidiaries operates the Pharmaceuticals Business. Our business consists of the operations, assets and liabilities that were previously the Ag Business. Solutia comprises the operations, assets and liabilities that were previously the Chemicals Business. The following table sets forth a chronology of events that resulted in the formation of Monsanto, Pharmacia and Solutia as three separate and distinct corporations. For more information regarding the relationships between Monsanto, Pharmacia, Pfizer and Solutia, please see our annual report on Form 10-K and quarterly reports on Form 10-Q, which are available on our website at http://www.monsanto.com.
Date of Event | Description of Event |
Sept. 1, 1997 | - Pharmacia (then known as Monsanto Company) entered into a Distribution Agreement with Solutia related to the transfer of the operations, assets and liabilities of the Chemical Business from Pharmacia (then known as Monsanto Company) to Solutia.
- Pursuant to the Distribution Agreement, Solutia assumed and agreed to indemnify Pharmacia (then known as Monsanto Company) for certain liabilities related to the Chemicals Business.
|
Dec. 19, 1999 | - Pharmacia (then known as Monsanto Company) entered into anagreement with Pharmacia & Upjohn, Inc. (PNU) relating to amerger (the Merger).
|
Feb. 9, 2000 | - We were incorporated in Delaware as a wholly owned subsidiaryof Pharmacia (then known as Monsanto Company) under the name“Monsanto Ag Company.”
|
March 31, 2000 | - Effective date of the Merger.
- In connection with the Merger, (1) PNU became a wholly owned subsidiary of Pharmacia (then known as Monsanto Company); (2) Pharmacia (then known as Monsanto Company) changed its name from “Monsanto Company” to “Pharmacia Corporation”; and (3) we changed our name from “Monsanto Ag Company” to “Monsanto Company.”
|
Sept. 1, 2000 | - We entered into a Separation Agreement with Pharmacia related to the transfer of the operations, assets and liabilities of the Ag Business from Pharmacia to us.
- Pursuant to the Separation Agreement, we were required to indemnify Pharmacia for any liabilities primarily related to the Ag Business or the Chemicals Business, and for liabilities assumed by Solutia pursuant to the Sept. 1, 1997 Distribution Agreement, to the extent that Solutia fails to pay, perform or discharge those liabilities.
|
Oct. 23, 2000 | - We completed an initial public offering in which we sold approximately 15 percent of the shares of our common stock to the public. Pharmacia continued to own 85% of our common stock.
|
July 1, 2002 | - Pharmacia, Solutia and we amended the Sept. 1, 1997, Distribution Agreement to provide that Solutia will indemnify us for the same liabilities for which it had agreed to indemnify Pharmacia and to clarify the parties’ rights and obligations.
- Pharmacia and we amended the Sept. 1, 2000 Separation Agreement to clarify our respective rights and obligations relating to our indemnification obligations.
|
Aug. 13, 2002 | - Pharmacia distributed the shares of our common stock that it owned to its shareowners via a tax-free stock dividend (the Monsanto Spinoff).
- As a result of the Monsanto Spinoff, Pharmacia no longer owns any equity interest in Monsanto.
|
April 16, 2003 | - Pursuant to a merger transaction, Pharmacia became a wholly owned subsidiary of Pfizer.
|
A-1
APPENDIX B |
|
BOARD OF DIRECTORS INDEPENDENCE STANDARDS |
ATTACHMENT A
to
BOARDOFDIRECTORS’ CHARTER
ANDCORPORATEGOVERNANCEGUIDELINES
INDEPENDENCESTANDARDS
An independent Director is one whom the Board affirmatively determines has no material relationship with the Company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the Company). The Board of Directors has adopted the following categorical standards to assist it in the determination of each Director’s independence. The Board of Directors will determine the independence of any Director with a relationship to the Company that is not covered by these standards and the Company will disclose the basis of such determinations and the identity of all directors who have been determined to be independent in the Company’s annual proxy statements.
A Director will be presumed to be independent if the Director:
1) Has not been an employee of the Company for at least three years, other than in the capacity as a former interim Chairman, Chief Executive Officer or other executive officer;
2) Has not, within the past three years, worked on the Company’s audit as a partner or employee of a firm that is the Company’s internal or external auditor, and is not a current partner or employee of such a firm;
3) Has not, during the last three years, been employed as an executive officer by a company for which an executive officer of the Company concurrently served as a member of such company’s compensation committee;
4) Has no immediate family members (i.e., spouse, parents, children, siblings, mothers and fathers-in-law, sons and daughters-in-law, brothers and sisters-in-law and anyone (other than domestic employees) who shares the Director’s home) who did not satisfy the foregoing criteria; provided, however, that, with respect to the employment criteria, such Director’s immediate family member may (i) serve or have served as an employee other than a partner in a firm that is the Company’s internal or external auditor, unless such family member has participated in the firm’s audit, assurance or tax compliance (other than tax planning) practice within the past three years, or personally worked on the Company’s audit during that time; and (ii) serve or have served as an employee but not as an executive officer of the Company during such period.
5) Has not received, and has no immediate family member who has received, during any twelve-month period within the last three years, more than $100,000 in direct compensation from the Company (other than in his or her capacity as a member of the Board of Directors or any committee of the Board or pension or other deferred compensation for prior service, provided that such compensation is not contingent in any way on continued service); provided, however, that neither compensation received by a Director for former service as an interim Chairman or CEO or other executive officer nor compensation received by a Director’s immediate family member for service as a non-executive employee shall be considered in determining independence;
6)Is not a current executive officer or employee, and has no immediate family member who is a current executive officer, of a company that made payments to, or received payments from, the Company for property or services in any of the last three fiscal years in an amount which, in any single fiscal year, exceeds the greater of $1 million, or 2% of such other company’s consolidated gross revenues as measured against the most recent completed fiscal year.
7) Has not been, and has no immediate family member who has been, an executive officer of a foundation, university, non-profit trust or other charitable organization, for which charitable contributions from the Company and its respective trusts or foundations, account or accounted for more than 2% or $1 million, whichever is greater, of such charitable organization’s consolidated gross revenues, in any single of the last three fiscal years, unless the Company discloses all contributions made to the recipient organization in its annual proxy statement; and
B-1
8) Does not serve, and has no immediate family member who has served, as an executive officer or general partner of an entity that has received an investment from the Company or any of its subsidiaries, unless such investment is less than $1 million or 2% of such entity’s total invested capital, whichever is greater, in any of the last three years.
In addition to the foregoing, in order to be considered independent for purposes of serving on the Company’s Audit and Finance Committee, a member of the Audit and Finance Committee may not, other than in his or her capacity as a member of the Audit and Finance Committee, the Board of Directors, or any other Board committee:
1) Accept, directly or indirectly, any consulting, advisory or other compensatory fee from the Company or any subsidiary of the Company, other than in the Director’s capacity as a director or committee member or any pension or other deferred compensation for prior service, provided that such compensation is not contingent in any way on continued service; or
2) Be an “affiliated person” of the Company or any subsidiary of the Company, as such term is defined by the Securities and Exchange Commission.
B-2
APPENDIX C |
|
BOARD OF DIRECTORS DESIRABLE CHARACTERISTICS OF DIRECTORS |
ATTACHMENT B
to
BOARDOF DIRECTORS’ CHARTER
AND CORPORATE GOVERNANCE GUIDELINES
DESIRABLE CHARACTERISTICSOF DIRECTORS
1. Personal Characteristics | | |
- Integrity and Accountability:
| | High ethical standards, integrity and strength of character in his or her personal and professional dealings and a willingness to act on and be accountable for his or her decisions. |
| | Demonstrate intelligence, wisdom and thoughtfulness in decision-making. Demonstrate a willingness to thoroughly discuss issues, ask questions, express reservations and voice dissent. |
| | An ability to read and understand balance sheets, income and cash flow statements. Understand financial ratios and other indices for evaluating Company performance. |
| | Assertive, responsible and supportive in dealing with others. Respect for others, openness to others’ opinions and the willingness to listen. |
| | History of achievements that reflect high standards for himself or herself and others. |
| | |
2. Core Competencies1 | | |
| | Experience in financial accounting and corporate finance, especially with respect to trends in debt and equity markets. Familiarity with internal financial controls. |
| | Record of making good business decisions and evidence that duties as a Director will be discharged in good faith and in a manner that is in the best interests of the Company. |
| | Experience in corporate management. Understand management trends in general and in the areas in which the Company conducts its business. |
| | Ability and time to perform during periods of both short-term and prolonged crisis. |
| | Unique experience and skills in an area in which the Company conducts its business, including science, manufacturing and technology relevant to the Company. |
| | Experience in global markets, international issues and foreign business practices. |
| | Understand and possess skills and have a history of motivating high-performing, talented managers. |
| | Skills and capacity to provide strategic insight and direction by encouraging innovations, conceptualizing key trends, evaluating strategic decisions, and challenging the Company to sharpen its vision. |
____________________
| | The Board as a whole needs the core competencies represented by at least several directors. |
C-1
3. Commitment to the Company | | |
| | Willing to commit the time and energy necessary to satisfy the requirements of Board and Board Committee membership. Expected to attend and participate in all Board meetings and Board Committee meetings in which they are a member. Encouraged to attend all annual meetings of shareholders. A willingness to rigorously prepare prior to each meeting and actively participate in the meeting. Willingness to make himself or herself available to management upon request to provide advice and counsel. |
- Awareness and Ongoing Education:
| | Possess, or be willing to develop, a broad knowledge of both critical issues affecting the Company (including industry-, technology- and market-specific information), and director’s roles and responsibilities (including the general legal principles that guide board members). |
| | In light of other existing commitments, ability to perform adequately as a Director, including preparation for and attendance at Board meetings and annual meetings of the shareholders, and a willingness to do so. |
| | Pursuant to the Monsanto Company Executive and Director Stock Ownership Requirements, if a non-employee director owns less than 10,000 shares or share equivalents of the Company’s common stock, the director is required to retain a specified portion of the shares of Company stock received as the result of exercising a stock option or pursuant to a restricted stock grant or other equity-based award granted under the Company’s long term incentive plans until the applicable stock ownership requirement is met. The required retention is net of the number of shares equal in value to the tax obligations with respect to the award, assuming such taxes are paid at the highest marginal rate. The retention percentage is 75% if a director owns or beneficially owns less than 5,000 shares of Company common stock and 50% if a director owns or beneficially owns more than 5,000 but less than 10,000 shares of Company common stock. |
| | |
4. Team and Company Considerations | |
| | Contributes talent, skills and experience that the Board needs as a team to supplement existing resources and provide talent for future needs. |
| | Contributes to the Board in a way that can enhance perspective and experiences through diversity in gender, ethnic background, geographic origin, and professional experience (public, private, and non-profit sectors). Nomination of a candidate should not be based solely on these factors. |
C-2
Directions from downtown St. Louis:
Take Interstate 64/Highway 40 west to I-170 north. Take I-170 north about 3 miles to the Olive Boulevard exit. Turn left and follow Olive approximately 3 miles to Old Olive Street Road. Turn left and immediately left again into Monsanto’s Creve Coeur Campus. Please follow the signs to the parking area and entrance to Building K.
Directions from St. Louis International Airport (Lambert):
Take Interstate 70 west to Lindbergh Boulevard south. Take Lindbergh Boulevard south about 6 miles to Olive Boulevard west exit. Follow Olive to the first traffic light. Proceed directly across the intersection and then immediately turn left into Monsanto’s Creve Coeur Campus. Please follow the signs to the parking area and entrance to Building K.
Notice of Annual Meeting
of Shareowners
and Proxy Statement
This Proxy Statement is printed entirely on recycled and recyclable paper. Soy ink, rather than petroleum-based ink, is used throughout.
PROXY
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS
OF MONSANTO COMPANY
The undersigned hereby appoints Hugh Grant and David F. Snively, and each of them, with power to act without the other and with power of substitution, as proxies and attorneys-in-fact and hereby authorizes them to represent and vote, as provided on the other side, all the shares of Monsanto Company common stock which the undersigned is entitled to vote and, in their discretion, to vote upon such other business as may properly come before the Annual Meeting of Shareowners of the Company to be held January 16, 2008 or any adjournment thereof, with all powers which the undersigned would possess if present at the meeting.
THIS PROXY CARD, WHEN PROPERLY EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN BY THE UNDERSIGNED. IF NO DIRECTION IS MADE BUT THE CARD IS SIGNED, THIS PROXY CARD WILL BE VOTED FOR THE ELECTION OF ALL NOMINEES UNDER ITEM 1, FOR ITEM 2, AGAINST ITEMS 3 AND 4, AND IN THE DISCRETION OF THE PROXIES WITH RESPECT TO SUCH OTHER BUSINESS AS MAY PROPERLY COME BEFORE THE MEETING.
(Continued, and to be marked, dated and signed, on the other side) |
Address Change/Comments(Mark the corresponding box on the reverse side) |
|
5FOLD AND DETACH HERE5
MONSANTO COMPANY
Annual Meeting of Shareowners
January 16, 2008
1:30 p.m. Central Standard Time
800 N. Lindbergh Blvd.
K Building
Creve Coeur, Missouri 63167
Please present this admission ticket and photo identification for the shareowner named on the front of this card for admittance to the annual meeting. For security purposes, bags and purses will be subject to search at the door. Seating at the meeting willbe limited and admittance will be based on space availability.
The Board of Directors recommends a vote FOR items 1 and 2 and AGAINST items 3 and 4. | Mark Here for Address Change or Comments | c | |
| PLEASE SEE REVERSE SIDE |
| | |
| | | | | | | | | | | FOR | | AGAINST | | ABSTAIN |
ITEM 1 - | ELECTION OF DIRECTOR NOMINEES: | | | | | | | | ITEM 2 - | RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM | | c | | c | | c |
| | | | | | | | | | | | | | | |
To be elected for terms expiring in 2011: | | FOR | | AGAINST | | ABSTAIN | | | | | FOR | | AGAINST | | ABSTAIN |
01 John W. Bachmann | | c | | c | | c | | ITEM 3 - | SHAREOWNER PROPOSAL ONE | | c | | c | | c |
|
| | FOR | | AGAINST | | ABSTAIN | | | | | FOR | | AGAINST | | ABSTAIN |
02 William U. Parfet | | c | | c | | c | | ITEM 4 - | SHAREOWNER PROPOSAL TWO | | c | | c | | c |
| | | | | | | | | | | | | | | |
| | FOR | | AGAINST | | ABSTAIN | | | | | | | WILL ATTEND | | |
03 George H. Poste, Ph.D., D.V.M. | | c | | c | | c | | If you plan to attend the Annual Meeting, please mark the WILL ATTEND box | | | | c | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
|
NOTE: Please sign as name appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such. |
5FOLD AND DETACH HERE5 |
WE ENCOURAGE YOU TO TAKE ADVANTAGE OF INTERNET OR TELEPHONE VOTING,
BOTH ARE AVAILABLE 24 HOURS A DAY, 7 DAYS A WEEK.
Internet and telephone voting is available through 11:59 PM Eastern Time
the day prior to annual meeting day.
Your Internet or telephone vote authorizes the named proxies to vote your shares in the same manner
as if you marked, signed and returned your proxy card.
INTERNET http://www.proxyvoting.com/mon Use the internet to vote your proxy. Have your proxy card in hand when you access the website. | OR | TELEPHONE 1-866-540-5760 Use any touch-tone telephone to vote your proxy. Have your proxy card in hand when you call. |
| | |
If you vote your proxy by Internet or by telephone, you do NOT need to mail back your proxy card. To vote by mail, mark, sign and date your proxy card and return it in the enclosed postage-paid envelope.
ChooseMLinkSMfor fast, easy and secure 24/7 online access to your future proxy materials, investment plan statements, tax documents and more. Simply log on toInvestor ServiceDirect®atwww.bnymellon.com/shareowner/isdwhere step-by-step instructions will prompt you through enrollment. |
You can view the Annual Report and Proxy Statement
on the internet at: http://www.monsanto.com